Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics

Lori K. Mattison, Richie Soong, Robert B Diasio

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

A prominent example of the potential application of pharmacogenomics and pharmacogenetics to oncology is the study of dihydropyrimidine dehydrogenase (DPD) in 5-fluorouracil (5-FU) metabolism. 5-FU is currently one of the most widely administered chemotherapeutic agents used for the treatment of epithelial cancers. DPD is the rate-limiting enzyme in the catabolism and clearance of 5-FU. The observation of a familial linkage of DPD deficiency from a patient exhibiting 5-FU toxicity suggested a possible molecular basis for variations in 5-FU metabolism. Molecular studies have suggested there is a relationship between allelic variants in the DPYD gene (the gene that encodes DPD) and a deficiency in DPD activity, providing a potential pharmacogenetic basis for 5-FU toxicity. In the last decade, studies have correlated tumoral DPD activity with 5-FU response, suggesting it may be a useful pharmacogenomic marker of patient response to 5-FU-based chemotherapy. This article reviews the basis and discusses the challenges of pharmacogenetic and pharmacogenomic testing of DPD for the determination of 5-FU efficacy and toxicity.

Original languageEnglish (US)
Pages (from-to)485-492
Number of pages8
JournalPharmacogenomics
Volume3
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Dihydrouracil Dehydrogenase (NADP)
Pharmacogenetics
Fluorouracil
Dihydropyrimidine Dehydrogenase Deficiency
Genes
Observation

Keywords

  • 5-FU
  • Dihydropyrimidine dehydrogenase
  • Dihydropyrimidine dehydrogenase deficiency
  • DPYD
  • Pharmacogenetic
  • Pharmacogenomic

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. / Mattison, Lori K.; Soong, Richie; Diasio, Robert B.

In: Pharmacogenomics, Vol. 3, No. 4, 2002, p. 485-492.

Research output: Contribution to journalArticle

@article{a753580f425c4e4189b50332cc34d1ab,
title = "Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics",
abstract = "A prominent example of the potential application of pharmacogenomics and pharmacogenetics to oncology is the study of dihydropyrimidine dehydrogenase (DPD) in 5-fluorouracil (5-FU) metabolism. 5-FU is currently one of the most widely administered chemotherapeutic agents used for the treatment of epithelial cancers. DPD is the rate-limiting enzyme in the catabolism and clearance of 5-FU. The observation of a familial linkage of DPD deficiency from a patient exhibiting 5-FU toxicity suggested a possible molecular basis for variations in 5-FU metabolism. Molecular studies have suggested there is a relationship between allelic variants in the DPYD gene (the gene that encodes DPD) and a deficiency in DPD activity, providing a potential pharmacogenetic basis for 5-FU toxicity. In the last decade, studies have correlated tumoral DPD activity with 5-FU response, suggesting it may be a useful pharmacogenomic marker of patient response to 5-FU-based chemotherapy. This article reviews the basis and discusses the challenges of pharmacogenetic and pharmacogenomic testing of DPD for the determination of 5-FU efficacy and toxicity.",
keywords = "5-FU, Dihydropyrimidine dehydrogenase, Dihydropyrimidine dehydrogenase deficiency, DPYD, Pharmacogenetic, Pharmacogenomic",
author = "Mattison, {Lori K.} and Richie Soong and Diasio, {Robert B}",
year = "2002",
doi = "10.1517/14622416.3.4.485",
language = "English (US)",
volume = "3",
pages = "485--492",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics

AU - Mattison, Lori K.

AU - Soong, Richie

AU - Diasio, Robert B

PY - 2002

Y1 - 2002

N2 - A prominent example of the potential application of pharmacogenomics and pharmacogenetics to oncology is the study of dihydropyrimidine dehydrogenase (DPD) in 5-fluorouracil (5-FU) metabolism. 5-FU is currently one of the most widely administered chemotherapeutic agents used for the treatment of epithelial cancers. DPD is the rate-limiting enzyme in the catabolism and clearance of 5-FU. The observation of a familial linkage of DPD deficiency from a patient exhibiting 5-FU toxicity suggested a possible molecular basis for variations in 5-FU metabolism. Molecular studies have suggested there is a relationship between allelic variants in the DPYD gene (the gene that encodes DPD) and a deficiency in DPD activity, providing a potential pharmacogenetic basis for 5-FU toxicity. In the last decade, studies have correlated tumoral DPD activity with 5-FU response, suggesting it may be a useful pharmacogenomic marker of patient response to 5-FU-based chemotherapy. This article reviews the basis and discusses the challenges of pharmacogenetic and pharmacogenomic testing of DPD for the determination of 5-FU efficacy and toxicity.

AB - A prominent example of the potential application of pharmacogenomics and pharmacogenetics to oncology is the study of dihydropyrimidine dehydrogenase (DPD) in 5-fluorouracil (5-FU) metabolism. 5-FU is currently one of the most widely administered chemotherapeutic agents used for the treatment of epithelial cancers. DPD is the rate-limiting enzyme in the catabolism and clearance of 5-FU. The observation of a familial linkage of DPD deficiency from a patient exhibiting 5-FU toxicity suggested a possible molecular basis for variations in 5-FU metabolism. Molecular studies have suggested there is a relationship between allelic variants in the DPYD gene (the gene that encodes DPD) and a deficiency in DPD activity, providing a potential pharmacogenetic basis for 5-FU toxicity. In the last decade, studies have correlated tumoral DPD activity with 5-FU response, suggesting it may be a useful pharmacogenomic marker of patient response to 5-FU-based chemotherapy. This article reviews the basis and discusses the challenges of pharmacogenetic and pharmacogenomic testing of DPD for the determination of 5-FU efficacy and toxicity.

KW - 5-FU

KW - Dihydropyrimidine dehydrogenase

KW - Dihydropyrimidine dehydrogenase deficiency

KW - DPYD

KW - Pharmacogenetic

KW - Pharmacogenomic

UR - http://www.scopus.com/inward/record.url?scp=0036020649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036020649&partnerID=8YFLogxK

U2 - 10.1517/14622416.3.4.485

DO - 10.1517/14622416.3.4.485

M3 - Article

C2 - 12164772

AN - SCOPUS:0036020649

VL - 3

SP - 485

EP - 492

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 4

ER -